secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2025-02-12T23:59:59+00:00
Accession:  0001104659-25-011852
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Kala Bio CEO Mark Iwicki resigns; Todd Bazemore named interim CEO
-----------------------------------------------------------------

- Mark Iwicki resigned as CEO effective Feb 11, 2025; remains Chair of Board.
- Board appointed Todd Bazemore as interim CEO and principal executive officer, effective immediately.
- Bazemore had been President since Dec 2021 and COO since Nov 2017.
- Prior roles include EVP/COO at Santhera and EVP/Chief Commercial Officer at Dyax.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000110465925011852/0001104659-25-011852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000110465925011852/tm256232d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-011852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer